ArticleInternational ophthalmology2025
Real-world evidence of long-term durability and efficacy of faricimab as an advanced treatment line for NVAMD and DME.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and durability of intravitreal Faricimab (Vabysmo) in patients with neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME).
methodsA retrospective study was conducted at a tertiary ophthalmology center. Eyes with NVAMD or DME which had received previous Anti-vascular endothelial growth factor (A-VEGF) treatment before switching to Faricimab were included. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and injection intervals were recorded at baseline and follow-up visits of up to 2.5 years.
resultsA total of 192 eyes (160 with NVAMD and 32 with DME) from 155 patients were included. The mean patient age was 79.5 ± 9.6 years, with an average follow-up duration of 468.1 ± 120.4 days from baseline. In the NVAMD cohort, BCVA improved from 0.43 ± 0.33 logMAR at baseline to 0.34 ± 0.30 at 1.5 years (p < 0.05). CST decreased significantly from a mean of 308.3 ± 65.3 Micrometers to 242.4 ± 44.8 Micrometers at two years (p < 0.001). The mean interval between injections increased from a mean of 33.9 ± 9.6 days at baseline to 77.6 ± 42.6 days at two years, reflecting a significant extension throughout the observation period (p < 0.001). In eyes with DME, CST declined from 403.6 ± 121.9 Micrometers at baseline to 303.2 ± 105.2 Micrometers at one year (p < 0.001), while BCVA remained stable. Injection intervals extended from 34.4 ± 10.3 to 60.9 ± 20.5 days at one year (p < 0.001).
conclusionIn this study of previously treated eyes with NVAMD and DME, Faricimab demonstrated sustained anatomical and functional benefits alongside meaningful injection interval extension.
Indexed as
Identifiers
41432839What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.